image credit: Adobe Stock

How biotech IPOs performed in the third quarter

October 3, 2023


Initial public offerings may slowly be coming back to the biotechnology sector.

Eight biotech companies priced IPOs from July through the end of September, raising $1.1 billion in total, according to data compiled by BioPharma Dive. That compares to four in the second quarter, which brought in about $580 million. (Kenvue, J&J’s consumer division, also completed an IPO in May as part of a spinout.)

A handful of other companies are lining up to test the waters, too, offering a glimpse into what could be a busier fourth quarter. Three biotechs, Lexeo Therapeutics, Abivax and Kairos Pharma, on Friday filed plans to go public.

Read More on Biopharma Dive